Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice

Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge

(2016) Yuichiro Amano et al.   HEPATOLOGY RESEARCH

Clinical approaches to non-alcoholic fatty liver disease

(2014) Katherine JP Schwenger   WORLD JOURNAL OF GASTROENTEROLOGY

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

(2013) Quentin M. Anstee et al.   Nature Reviews Gastroenterology & Hepatology

Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway

(2012) Wei Zhang et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study

(2012) Yuichiro Eguchi et al.   JOURNAL OF GASTROENTEROLOGY

Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2012) Yoshihisa Takahashi   WORLD JOURNAL OF GASTROENTEROLOGY

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

(2011) E. Boettcher et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial

(2011) Dawn M. Torres et al.   HEPATOLOGY

From the metabolic syndrome to NAFLD or vice versa?

(2010) Ester Vanni et al.   DIGESTIVE AND LIVER DISEASE

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?

(2008) Eugen Florin Georgescu   ADVANCES IN THERAPY

Cytokines and Renin-Angiotensin System Signaling in Hepatic Fibrosis

(2008) Montserrat Moreno et al.   Clinics in Liver Disease

Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease

(2008) Hai-Ning Wang et al.   WORLD JOURNAL OF GASTROENTEROLOGY